News
Künstliche Intelligenz in der Medizin: OP-Risiken mindern
Einen kognitiven medizinischen Assistenten entwickeln Wissenschaftler des Universitätsklinikum Heidelberg. Die künstliche Intelligenz soll im Vorfeld einer Operation Risiken erkennen und Komplikationen vorbeugen.biosaxony-Netzwerkpartner stellt sich vor: BARMER Landesvertretung Sachsen
Digitale Grenzgänger: CASUS am weltweit größten Supercomputer Frontier beteiligt
Seit einem Jahr unterstützen Wissenschaftler*innen von CASUS, dem Center for Advanced Systems Understanding am Helmholtz-Zentrum Dresden-Rossendorf (HZDR), den Aufbau des weltweit größten geplanten Exascale-Computers Frontier. Die Zusammenarbeit mit der University of Delaware trägt nun erste Früchte: Die Forscher*innen testeten ihre Simulationssoftware PIConGPU erfolgreich auf einer der weltschnellsten Grafikkarten für Hochleistungsrechner – der erst kürzlich erschienen MI100 des US-amerikanischen Unternehmens AMD.Heal Capital erreicht 100 Mio. Euro Zielvolumen
Die privaten Krankenversicherer haben mehr als 100 Millionen Euro in den Venture-Capital-Fonds Heal Capital investiert, der digitale Innovationen für die Gesundheitsversorgung fördert.Maxon und Fourier arbeiten künftig bei Exoskeletten und Robotiksystemen zusammen
Präzisions-Antriebssysteme von Maxon und die robotische Rehabilitation des Start-ups Fouriers aus Shanghai sollen künftig in einer globalen Partnerschaft neue Technologien für Patienten ermöglichen.T4M Start-up World 2021: Bis Februar bewerben
Die T4M Start-up World soll 2021 wachsen. Über 40 Gründerteams haben sich bereits angemeldet. Bis Anfang Februar können sich weitere bewerben.Online Event: Digital Medicine Week 2021
Vom 2. bis 5. Februar informiert der Health Innovation Hub des BMG über digitale Innovationen, DiGA und MDR für digitale Medizinprodukte.Initiative Medtech 2030 soll Produktions- und Forschungsstandort Deutschland stärken
Zur Bundestagswahl 2021 fordert der BVMed in einem 12-Punkte-Positionspapier eine Gesamtstrategie für die Medizintechnik-Branche. Mit der Initiative Medtech 2030 will der Verband eine stärkere Verzahnung von Gesundheits-, Wirtschafts- und Forschungspolitik erreichen.BIOVISION Catalyzer & Investor Conference
BIOVISION 2015 edition will be held, on April 15 & 16, at the Cité Internationale, in Lyon – France and highlights will include the 3rd edition of Catalyzer and Investor Conference.
1 / The BIOVISION Catalyzer Pitches will allow selected innovative projects and seed stage startups to connect with potential private and public partners while pitching in front of a prestigious selection committee from academia, industry, investors and civil society, co-chaired by Michel Goldman, Executive Director of Innovative Medicines Initiative and Alexander von Gabain, Deputy Vice-Chancellor for Innovation and Corporate Alliances at the Karolinska Institute.
2/ The BIOVISION Investor Conference is an international prestigious investor event connecting Medtech, Biotech, e-Health start-ups and mid-sized companies with relevant partners and financial investors. It includes workshops and Pitches sessions for selected companies seeking visibility, collaborations and/or funds within 18 months. The 2015 selection committee is co-chaired by Florent Gros, Managing Director at Novartis Venture Funds and Anne Horgan, Associate at Sofinnova Partners.
Applications are open to every company or research groups in Europe and worldwide – the submission deadline is February 28th. Please find enclosed the call for applications.
Please find more information about the forum: www.biovision.org
About Catalyzer: www.biovision.org/catalyzer.php
About Investor Conference: www.biovision.org/IC.php
Contact:Emilie ROMEOChargée d’affaires EuropeEuropean Project ManagerLyonbiopôle321 avenue Jean Jaurès69007 LYON (France)T : + 33.(0)4.72.76.53.44Mob : +33.(0)6.42.57.95.19Mail: romeo@lyonbiopole.com
********
About BIOVISION
BIOVISION is an international forum devoted to the life sciences. The aim is to discuss forward-looking opportunities and to facilitate collaboration between the various stakeholders, to encourage innovation and ultimately ensure public access to knowledge and solutions. Founded in 1999, BIOVISION is driven by an independent not-for-profit organization, the Foundation for the University of Lyon in France (the Fondation pour l’Université de Lyon.)
The forum has a global reach and brings together a large number of leading figures every year in Lyon. Participants include researchers, policy-makers, investors and entrepreneurs; from startups to multinationals. Together, these multidisciplinary decision-makers reflect on the future advances in life sciences and consult on how to convert discoveries by researchers into practical, innovative solutions with a public health benefit. They directly address business models and funding solutions.
To foster innovation BIOVISION has introduced two themed sessions:
The BIOVISION Catalyzer is organized jointly with Lyonbiopôle, a world competitiveness cluster in the field of life sciences, to promote projects originating from public-private partnerships.
The BIOVISION Investor Conference is organized jointly with Lyonbiopôle and France Biotech to discuss funding and identify promising start-ups and innovative companies. An online networking platform and on-site meeting areas foster and support these discussions.
BIOVISION also hosts live streamed sessions to raise awareness and engage communities in scientific issues around the health care challenges of tomorrow. BIOVISION enjoys the support of the Greater Lyon, Rhône department and Rhône-Alpes authorities.
To register, go to: http://biovision.inviteo.fr
More information: http://www.biovision.org
About the Fondation pour l’Université de Lyon
Chaired by Alain Mérieux, the purpose of the Fondation is to support the University of Lyon in its ambition to be one of Europe’s ten largest higher education and research clusters. The seven active founders of the Fondation (banking group BNP Paribas, the French Deposits and Consignments Fund, CIC bank, retailer Casino, the Institut Mérieux, pharmaceutical group Sanofi and Lyon-based domestic appliance manufacturer SEB) help it to fulfill its remit of promoting the international recognition of the University of Lyon, contributing to its excellence, and strengthening its ties with the territory.
For the Fondation, BIOVISION is a key element of the region’s international profile in one of its areas of excellence; the life sciences. The forum also contributes directly to the economic development of the area through innovation.